Astex
  • Discover Astex
    • Our Mission & Values
    • Our Leadership Team
      • UK – Discovery Research
        • Jeremy Carmichael
        • Harren Jhoti
        • Michelle Jones
        • Neil Jones
        • John Lyons
        • Chris Murray
        • David Rees
        • Nicola Wallis
        • Nicola Wilsher
      • USA – Product Development
        • Mohammad Azab
        • Martin Buckland
        • Harold N. Keer
        • Nipun Davar
        • Yong Hao
        • Joseph Iovino
        • Samuel Jason
        • Nancy Worrell
        • Patti Oto
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
      • Proprietary Products and Programs
        • Guadecitabine (SGI-110) DNMT inhibitor (Hematological Malignancies and Solid Tumors)
        • ASTX029 Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
        • Oral Decitabine and Cedazuridine (ASTX727) (Hematological Malignancies)
        • ASTX660 Dual IAP Antagonist (Solid Tumors & Lymphomas)
      • Partnered Products and Programs
        • Kisqali® (ribociclib) CDK4/6 inhibitor (Oncology)
        • Balversa® (erdafitinib) FGFr inhibitor (Oncology)
        • AZD5363 PKB/Akt Inhibitor (Oncology)
        • Multiple Targets and Therapeutic Areas
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation
  • Partnering
  • Our People
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Astex in the News
  • Contact
  • Search
  • Menu Menu
You are here: Home1 / 2014: ASH First clinical results of P2 study of SGI-110 in intermediate...

2014: ASH First clinical results of P2 study of SGI-110 in intermediate or high risk MDS or CMML

25 November 2014/in Uncategorised /by webadmin

2014: ASH First clinical results of P2 study of SGI-110 in intermediate or high risk MDS or CMML

/wp-content/uploads/2019/11/logo_white.png 0 0 webadmin /wp-content/uploads/2019/11/logo_white.png webadmin2014-11-25 15:42:262016-12-01 13:01:032014: ASH First clinical results of P2 study of SGI-110 in intermediate or high risk MDS or CMML

Copyright © Astex Pharmaceuticals
All rights reserved

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal

Member of the Otsuka Group

2014: ESMO Study of HSP90 Inhibitor AT13387 alone and combo w/ Crizotinib in... 2014: ASH First clinical results of P2 study of SGI-110 in intermediate or high...
Scroll to top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok